Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intranasal Naloxone Administration.
Skulberg AK, Tylleskar I, Dale O. Skulberg AK, et al. Among authors: dale o. N Engl J Med. 2021 Jun 17;384(24):e96. doi: 10.1056/NEJMc2106983. N Engl J Med. 2021. PMID: 34133872 No abstract available.
Pharmacokinetics of a new, nasal formulation of naloxone.
Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Tylleskar I, et al. Among authors: dale o. Eur J Clin Pharmacol. 2017 May;73(5):555-562. doi: 10.1007/s00228-016-2191-1. Epub 2017 Jan 31. Eur J Clin Pharmacol. 2017. PMID: 28144724
International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
McDonald R, Danielsson Glende Ø, Dale O, Strang J. McDonald R, et al. Among authors: dale o. Drug Alcohol Rev. 2018 Feb;37(2):205-215. doi: 10.1111/dar.12571. Epub 2017 Jun 8. Drug Alcohol Rev. 2018. PMID: 28597483 Review.
These have potential to deliver a therapeutic dose in 0.1 mL volume. [McDonald R, Danielsson Glende O, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of th …
These have potential to deliver a therapeutic dose in 0.1 mL volume. [McDonald R, Danielsson Glende O, Dale O, Strang J …
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use.
Skulberg AK, Tylleskär I, Braarud AC, Dale J, Heyerdahl F, Mellesmo S, Valberg M, Dale O. Skulberg AK, et al. Among authors: dale o, dale j. BMJ Open. 2020 Nov 12;10(11):e041556. doi: 10.1136/bmjopen-2020-041556. BMJ Open. 2020. PMID: 33184084 Free PMC article.
423 results